Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market

Rhea-AI Filing Summary

Amicus Therapeutics President and CEO Bradley L. Campbell sold 22,500 shares of common stock in an open-market transaction. The sale took place at a weighted average price of $14.3484 per share on March 2, 2026, with individual trade prices ranging from $14.34 to $14.37. After this transaction, he continues to hold 998,680 shares of Amicus Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Bradley L

(Last) (First) (Middle)

47 HULFISH STREET

(Street)

PRINCETON NJ 08542

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S		22,500	D	$14.3484(1)	998,680	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.34 to $14.37 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.

	/s/ Christian Formica, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amicus Therapeutics (FOLD) CEO Bradley Campbell report in this Form 4?

Amicus Therapeutics CEO Bradley L. Campbell reported selling 22,500 shares of common stock. The transaction was an open-market sale on March 2, 2026, at a weighted average price of $14.3484 per share, and he retained 998,680 shares afterward.

How many Amicus Therapeutics (FOLD) shares did the CEO sell and at what price?

Bradley L. Campbell sold 22,500 shares of Amicus Therapeutics common stock. The weighted average sale price was $14.3484 per share, with individual trades executed between $14.34 and $14.37, according to the detailed pricing footnote in the filing.

How many Amicus Therapeutics (FOLD) shares does the CEO still own after this sale?

Following the reported sale, Bradley L. Campbell directly owns 998,680 shares of Amicus Therapeutics common stock. This figure represents his remaining direct holdings after disposing of 22,500 shares in the open-market transaction disclosed in the Form 4.

What type of transaction did the Amicus Therapeutics (FOLD) CEO disclose?

The CEO disclosed an open-market sale of common stock, coded as “S” in the Form 4. This indicates a sale in the open market or a private transaction, with 22,500 shares sold at a weighted average price of $14.3484 per share.

Does the Form 4 for Amicus Therapeutics (FOLD) mention a price range for the CEO’s sale?

Yes. A footnote states that the reported weighted average price of $14.3484 reflects multiple trades. The individual sale prices for these 22,500 shares ranged from $14.34 to $14.37, and detailed trade information is available upon request.